ChiCTR-IPR-15006209 版本V1.3 版本创建时间2017/09/01 14:37:07 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR-IPR-15006209 

最近更新日期:

Date of Last Refreshed on:

2017-08-01 17:59:42 

注册时间:

Date of Registration:

2015-03-31 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

术中两种麻醉维持方式对老年恶性肿瘤患者术后近期谵妄发生率和远期存活时间的影响:标签开放的随机对照研究

Public title:

Impact of two anesthesia maintenance methods on incidence of early delirium and duration of long-term survival in elderly patients after surgery for malignant tumor: an open-label, randomized controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

术中两种麻醉维持方式对老年恶性肿瘤患者术后近期谵妄发生率和远期存活时间的影响:标签开放的随机对照研究

Scientific title:

Impact of two anesthesia maintenance methods on incidence of early delirium and duration of long-term survival in elderly patients after surgery for malignant tumor: an open-label, randomized controlled trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张玥 

研究负责人:

王东信 

Applicant:

Yue Zhang 

Study leader:

Dong-Xin Wang 

申请注册联系人电话:

Applicant telephone:

+86 13718781933

研究负责人电话:

Study leader's
telephone:

+86 13910731903

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zyzy1933@163.com

研究负责人电子邮件:

Study leader's E-mail:

wangdongxin@hotmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市西城区西什库大街8号

研究负责人通讯地址:

北京市西城区西什库大街8号

Applicant address:

8 Xishiku street, Xicheng district, Beijing

Study leader's address:

8 Xishiku street, Xicheng district, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京大学第一医院

Applicant's institution:

Peking University First Hospital

研究负责人所在单位:

北京大学第一医院

Affiliation of the Leader:

Peking University First Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2015[869]

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

北京大学第一医院临床研究伦理委员会

Name of the ethic committee:

Clinical Research Ethics Committee of Peking University First Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2015-03-30 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京大学第一医院

Primary sponsor:

Peking University First Hospital

研究实施负责(组长)单位地址:

北京市西城区西什库大街8号

Primary sponsor's address:

8 Xishiku street, Xicheng district, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学第一医院

具体地址:

西什库大街8号

Institution
hospital:

Peking University First Hospital

Address:

8 Xishiku Street, Xicheng District

经费或物资来源:

北京大学第一医院麻醉科

Source(s) of funding:

Department of Anesthesiology, Peking University First Hospital

研究疾病:

恶性肿瘤  

Target disease:

Malignant tumor

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

主要目的:比较术中七氟烷吸入麻醉和丙泊酚静脉麻醉两种麻醉维持方式对老年恶性肿瘤病人术后7天内谵妄发生率的影响差异。 次要目的:比较术中七氟烷吸入麻醉和丙泊酚静脉麻醉两种麻醉维持方式对老年恶性肿瘤病人术后以下结局的影响差异 1)术后30天认知功能障碍发生率; 2)术后30天内并发症发生率和术后30天全因死亡率; 3)术后3年存活时间和存活率; 4)术后3年存活病人生活质量。  

Objectives of Study:

Primary end point: to investigate the effects of two anesthesia maintenance methods (inhalational sevoflurane vs intravenous propofol) on the incidence of early postoperative delirium; Secondary end points: to investigate the effects of two anesthesia maintenance methods (inhalational sevoflurane vs intravenous propofol) on the following outcomes: 1) the incidence of postoperative cognitive dysfunction at 1 month after surgery; 2) the incidence of 30-day postoperative complications and 30-day all-cause mortality after surgery; 3) the duration of survival within 3 years after surgery and the rate of survival at 3 years after surgery; 4) the quality of life at 3 years after surgery.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

入选标准:本研究的受试者必须符合下列所有条件:
1)年龄≥65岁且<90岁,性别、民族不限;
2)拟在全身麻醉下行择期/限期恶性肿瘤治疗手术,预计手术时间≥2小时;
3)原发肿瘤,手术前未经过放疗、化疗的治疗措施;
4)同意参加本研究,并签署知情同意书

Inclusion criteria

Participants must meet all of the following criteria:
1) To be aged from 65 years to 90 years;
2) Planning to undergo elective surgery for malignant tumor under general anesthesia, with an expected duration of surgery longer than 2 hours;
3) Primary malignant tumors, without preoperative radiotherapy and/or chemotherapy;
4) Agree to participate in the study, and sign the writen informed consent.

排除标准:

受试者存在下列任何一种情况即不能进入本项研究:
1)拒绝参加本研究;
2)既往有精神分裂症、癫痫或帕金森病史;因严重痴呆、语言障碍、昏迷等情况无法完成术前评估;
3)病情危重(术前ASA分级≥Ⅳ级者);严重肾功能损害(血肌酐>442μmol/L,伴或不伴有血钾> 6.5 mmol/L,或临床医生认为需行肾脏替代治疗者);严重肝功能损害(Child-Pugh分级C级);
4)颅脑手术;
5)主治医生或研究者认为存在其他不宜参加本研究的情况。

Exclusion criteria:

Patients will be excluded if they meet any of the following criteria:
1) Refuse to participate;
2) Preoperative history of schizophrenia, epilepsy or parkinsonism, or inability to communicate during the preoperative evaluation because of coma, profound dementia or language barrier;
3) Critically ill (ASA classification IV or above); severe renal dysfunction (serum creatinine >442 umol/L, with or without potassium >6.5 mmol/L; or requirement of renal replacement therapy); severe hepatic dysfunction (Child-Pugh class C);
4) Brain injury or neurosurgery;
5) Any other conditions that are considered unsuitable to participate by the attending physicians or researchers.

研究实施时间:

Study execute time:

From 2015-03-31 00:00:00 To 2021-03-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2015-04-01 00:00:00 To 2018-03-31 00:00:00

干预措施:

Interventions:

组别:

七氟烷组

样本量:

614

Group:

Sevoflurane group

Sample size:

干预措施:

采用七氟烷吸入维持麻醉

干预措施代码:

Intervention:

Anesthesia is maintained with inhalation of sevoflurane

Intervention code:

组别:

丙泊酚组

样本量:

614

Group:

Propofol group

Sample size:

干预措施:

采用丙泊酚静脉输注维持麻醉

干预措施代码:

Intervention:

Anesthesia is maintained with intravenous infusion of propofol

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学第一医院 

单位级别:

三甲医院 

Institution
hospital:

Peking University First Hospital

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

河北 

市(区县):

 

Country:

China

Province:

Hebei

City:

单位(医院):

河北医科大学第四医院 

单位级别:

三甲医院 

Institution
hospital:

The Fourth Hospital of Hebei Medical University

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

宁夏回族自治区 

市(区县):

 

Country:

China

Province:

Ningxia Hui Autonomous Region

City:

单位(医院):

宁夏自治区人民医院 

单位级别:

三甲医院 

Institution
hospital:

People's Hospital of Ningxia Hui Autonomous Region

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京世纪坛医院 

单位级别:

三甲医院 

Institution
hospital:

Beijing Shijitan Hospital

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

贵州 

市(区县):

 

Country:

China

Province:

Guizhou

City:

单位(医院):

贵州省人民医院 

单位级别:

三甲医院 

Institution
hospital:

Guizhou Provincial People's Hospital

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

青海 

市(区县):

 

Country:

China

Province:

Qinghai

City:

单位(医院):

青海大学附属医院 

单位级别:

三甲医院 

Institution
hospital:

Qinghai University Affiliated Hospital

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

湖南 

市(区县):

 

Country:

China

Province:

Hunan

City:

单位(医院):

中南大学湘雅三医院 

单位级别:

三甲医院 

Institution
hospital:

The Third Xiangya Hospital of Central South University

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

广西壮族自治区 

市(区县):

 

Country:

China

Province:

Guangxi Zhuang Autonomous Region

City:

单位(医院):

广西医科大学附属肿瘤医院 

单位级别:

三甲医院 

Institution
hospital:

Affiliated Tumor Hospital of Guangxi Medical University

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

山西 

市(区县):

 

Country:

China

Province:

Shanxi

City:

单位(医院):

山西省人民医院 

单位级别:

三甲医院 

Institution
hospital:

Shanxi Provincial People's Hospital

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

东南大学附属中大医院 

单位级别:

三甲医院 

Institution
hospital:

Southeast University Zhongda Hospital

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

河南 

市(区县):

 

Country:

China

Province:

Henan

City:

单位(医院):

郑州大学第一医院 

单位级别:

三甲医院 

Institution
hospital:

the First Affiliated Hospital of Zhengzhou University

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

陕西 

市(区县):

 

Country:

China

Province:

Shannxi

City:

单位(医院):

西安第四军医大学唐都医院 

单位级别:

三甲医院 

Institution
hospital:

Tangdu Hospital of the Fourth Military Medical University

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津南开医院 

单位级别:

三甲医院 

Institution
hospital:

Tianjin Nankai Hospital

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

深圳市第二人民医院 

单位级别:

三甲医院 

Institution
hospital:

Shenzhen Second People’s Hospital

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

术后7天谵妄发生率

指标类型:

主要指标

Outcome:

The incidence of delirium during the first 7 days after surgery

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后30天内并发症发生率

指标类型:

次要指标

Outcome:

Incidence of postoperative complications within 30 days after surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后无复发存活时间

指标类型:

次要指标

Outcome:

Recurrence-free survival after surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后30天认知功能

指标类型:

次要指标

Outcome:

Cognitive function at 30 days after surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后3年认知功能

指标类型:

附加指标

Outcome:

Cognitive function at the 3rd year after surgery

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后3年生活质量

指标类型:

附加指标

Outcome:

Quality of life at the 3rd year after surgery

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后总存活时间

指标类型:

主要指标

Outcome:

Duration of overall survival after surgery

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后无事件存活时间

指标类型:

次要指标

Outcome:

Event-free survival after surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后3天疼痛评分

指标类型:

附加指标

Outcome:

The intensity of pain during postoperative days 1-3

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后7天主观睡眠评分

指标类型:

附加指标

Outcome:

The subjective sleep quality during postoperative days 1-7

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后入ICU比例

指标类型:

次要指标

Outcome:

The percentage of intensive care unit (ICU) admission after surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后带管入ICU比例

指标类型:

次要指标

Outcome:

The proportion of ICU admission with endotracheal intubation after surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后ICU停留时间

指标类型:

次要指标

Outcome:

The length of stay in ICU after surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后住院时间

指标类型:

次要指标

Outcome:

The length of stay in hospital after surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后7天认知功能

指标类型:

附加指标

Outcome:

Cognitive function at 7 days after surgery

Type:

Additional indicator

测量时间点:

测量方法:

部分病人

Measure time point of outcome:

Measure method:

Selected patients

指标中文名:

血清维生素D浓度

指标类型:

附加指标

Outcome:

Serum vitamin D concentration

Type:

Additional indicator

测量时间点:

测量方法:

部分病人

Measure time point of outcome:

Measure method:

Selected patients

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 65 years
最大 Max age 90 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由统计专家利用计算机软件产生随机数字序列

Randomization Procedure (please state who generates the random number sequence and by what method):

Random number sequence is generated by a biostatistician using a computer software

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

本研究为标签开放的随机对照研究,但随访者不参加病人的麻醉及围术期管理。

Blinding:

This is an open-label, randomized controlled trial. Investigators who perform postoperative follow-up do not participate in anesthesia and perioperative care of patients.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

北京大学第一医院麻醉科

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Department of Anesthesiology, Peking University First Hospital

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

北京大学第一医院医学统计实验室

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Department of Biostatistics, Peking University First Hospital

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2015-04-07 21:30:24